 |
Top 6 Flu treatment startups
Updated: May 07, 2024 | Editor: Jason Kwon |
Flu treatment startups are focused on developing innovative technologies such as antiviral therapeutics, rapid diagnostic tests, and digital platforms for symptom tracking and remote consultations. These startups aim to revolutionize flu management by providing more effective treatment options, enabling early detection and intervention, and improving access to care, ultimately reducing the impact of flu outbreaks and enhancing public health preparedness.
1
Country: USA | Funding: $908.6M
Vir Biotechnology brings together cutting-edge innovations with scientific expertise and management.
Vir Biotechnology brings together cutting-edge innovations with scientific expertise and management.
2
Country: USA | Funding: $213.1M
Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral
Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral
3
Country: USA | Funding: $125.4M
Visterra is a clinical-stage biopharmaceutical company focused on applying its novel Hierotope platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines for infectious and non-infectious diseases.
Visterra is a clinical-stage biopharmaceutical company focused on applying its novel Hierotope platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines for infectious and non-infectious diseases.
4
Country: China | Funding: $96.3M
Sinovac Biotech is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) ...
Sinovac Biotech is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) ...
5
Country: USA | Funding: $65.6M
Codagenix employs a proprietary technology platform for the construction of live attenuated viral vaccines for flu and other targets.
Codagenix employs a proprietary technology platform for the construction of live attenuated viral vaccines for flu and other targets.
6
Country: Australia
Vaxine is focused on development of innovative vaccine technologies. Vaxine’s human candidates include vaccines against seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, rabies, and allergy.
Vaxine is focused on development of innovative vaccine technologies. Vaxine’s human candidates include vaccines against seasonal and pandemic influenza, hepatitis B, Japanese encephalitis, West Nile Virus, malaria, rabies, and allergy.
